Selected article for: "immune response and post onset"
Author: Sarina Yang, He; Racine-Brzostek, Sabrina E.; Lee, William T.; Hunt, Danielle; Yee, Jim; Chen, Zhengming; Kubiak, Jeffrey; Cantu, Miguel; Hatem, Layla; Zhong, Elaine; D'Ambrosio, Danielle; Chadburn, Amy; Westblade, Lars; Glesby, Marshall; Loda, Massimo; Cushing, Melissa M.; Zhao, Zhen
Title: SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays
  • Cord-id: zovj2vt5
  • Document date: 2020_6_4
    • ID: zovj2vt5
    Snippet: BACKGROUND: In the ongoing COVID-19 pandemic, there is an urgent need for comprehensive performance evaluation and clinical utility assessment of serological assays to understand the immune response to SARS-CoV-2. METHODS: IgM/IgG and total antibodies against SARS-CoV-2 were measured by a cyclic enhanced fluorescence assay (CEFA) and a microsphere immunoassay (MIA), respectively. Independent performance evaluation included imprecision, reproducibility, specificity and cross-reactivity (CEFA n=32
    Document: BACKGROUND: In the ongoing COVID-19 pandemic, there is an urgent need for comprehensive performance evaluation and clinical utility assessment of serological assays to understand the immune response to SARS-CoV-2. METHODS: IgM/IgG and total antibodies against SARS-CoV-2 were measured by a cyclic enhanced fluorescence assay (CEFA) and a microsphere immunoassay (MIA), respectively. Independent performance evaluation included imprecision, reproducibility, specificity and cross-reactivity (CEFA n=320, MIA n=364). Clinical utility was evaluated by both methods in 87 patients at initial emergency department visit, 28 during subsequent hospitalizations (106 serial samples), and 145 convalescent patients. Totally 916 patients and 994 samples were evaluated. RESULTS: Agreement of CEFA and MIA was 90.4%-94.5% (Kappa: 0.81-0.89) in 302 samples. CEFA and MIA detected SARS-CoV-2 antibodies in 26.2% and 26.3%, respectively, of ED patients. Detection rates increased over time reaching 100% after 21 days post-symptom onset. Longitudinal antibody kinetic changes by CEFA and MIA measurements correlated well and exhibited three types of seroconversion. Convalescent sera showed a wide range of antibody levels. CONCLUSION: Rigorously validated CEFA and MIA assays are reliable for detecting antibodies to SARS-CoV-2 and show promising clinical utility when evaluating immune response in hospitalized and convalescent patients, but are not useful for early screening at patient’s initial ED visit.

    Search related documents:
    Co phrase search for related documents
    • academic clinical laboratory and acute respiratory syndrome coronavirus: 1
    • accurate identification and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accurate identification and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • accurate identification and additional information: 1, 2
    • acute respiratory and additional information: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and additional methodology: 1
    • acute respiratory and long time period: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory and luminex corporation: 1
    • acute respiratory syndrome coronavirus and additional information: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and additional methodology: 1
    • acute respiratory syndrome coronavirus and long time period: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome coronavirus and luminex corporation: 1
    • acute symptom and additional information: 1
    • acute symptom and long time period: 1